BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18823813)

  • 1. Plasma amantadine concentrations in patients with Parkinson's disease.
    Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M
    Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
    Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A
    Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
    Malsch U; Bliesath H; Böther K; Ramm H; Lühmann R
    Fortschr Neurol Psychiatr; 2001 Feb; 69(2):86-9. PubMed ID: 11253562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
    Gondim Fde A; Costa HA; Taunay TC; de Oliveira GR; Ferreira JM; Rola FH
    Mov Disord; 2010 Jul; 25(10):1505-6. PubMed ID: 20629118
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
    Yeh HH; Yang YH; Chen SH
    Electrophoresis; 2010 Jun; 31(11):1903-11. PubMed ID: 20446294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amantadine in Parkinson's disease: pro and contra.
    Greulich W; Fenger E
    J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
    Kubo S; Iwatake A; Ebihara N; Murakami A; Hattori N
    Parkinsonism Relat Disord; 2008; 14(2):166-9. PubMed ID: 17509924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An artist's view of drug-induced hallucinosis.
    Ebersbach G
    Mov Disord; 2003 Jul; 18(7):833-4. PubMed ID: 12815666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dropped head associated with amantadine in Parkinson disease.
    Kataoka H; Ueno S
    Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine-induced livedo reticularis: a report of two cases.
    Hayes BB; Cook-Norris RH; Miller JL; Rodriguez A; Zic JA
    J Drugs Dermatol; 2006 Mar; 5(3):288-9. PubMed ID: 16573266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
    Postma JU; Van Tilburg W
    J Am Geriatr Soc; 1975 May; 23(5):212-5. PubMed ID: 123540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amantadine induced reversible corneal edema.
    Deogaonkar M; Wilson K; Vitek J
    J Clin Neurosci; 2011 Feb; 18(2):298-9. PubMed ID: 21163653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between amantadine and the onset of dementia in Parkinson's disease.
    Inzelberg R; Bonuccelli U; Schechtman E; Miniowich A; Strugatsky R; Ceravolo R; Logi C; Rossi C; Klein C; Rabey JM
    Mov Disord; 2006 Sep; 21(9):1375-9. PubMed ID: 16705684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients.
    Müller T; Kuhn W; Quack G; Przuntek H
    J Neural Transm Suppl; 1995; 46():407-13. PubMed ID: 8821076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of amantadine in Parkinson's disease.
    Campbell AM; Williams MJ
    Br J Clin Pract; 1972 Jan; 26(1):19-22. PubMed ID: 4554563
    [No Abstract]   [Full Text] [Related]  

  • 19. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 20. Memantine-induced myoclonus and delirium exacerbated by trimethoprim.
    Moellentin D; Picone C; Leadbetter E
    Ann Pharmacother; 2008 Mar; 42(3):443-7. PubMed ID: 18303133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.